Overview of the Fundraise
Artemis Medicare Services has received board approval to raise up to Rs 700 crore through a Qualified Institutional Placement (QIP) or preferential allotment. Furthermore, the fundraise may also include equity shares, convertible and non-convertible debentures, and warrants. Consequently, these funds will support new hospital projects and organic expansion across India. The raise is subject to shareholder and regulatory clearances.
The capital infusion targets a reduction of net debt to Rs 250–280 crore. Thus, the move signals a clear shift toward aggressive growth investment rather than debt consolidation alone.
Q3 FY26 Financial Performance
Revenue and Profit Growth
Artemis Medicare Services reported strong results for Q3 FY26. Consolidated revenue from operations reached INR 272 crore, reflecting 17.2% year-on-year growth. Additionally, revenue for the nine-month period of FY26 climbed to INR 802 crore — up 15.1% from the prior year.
Profit After Tax (PAT) for Q3 FY26 grew 7.9% year-on-year to INR 22 crore. Moreover, for the nine-month period, PAT rose significantly to INR 73 crore compared to INR 59 crore in the same period of FY25.
EBITDA and Margins
EBITDA for Q3 FY26 stood at INR 52 crore, with an EBITDA margin of 9.1%. However, the nine-month EBITDA margin reached a stronger 19.8% — indicating that quarterly margins faced some pressure. Management attributes this partly to higher employee costs, which are expected to stabilize as occupancy rates improve.
Average Revenue Per Occupied Bed (ARPOB) rose 10% year-on-year to INR 84,100 in Q3 FY26. Meanwhile, occupancy at the flagship Gurugram hospital improved to 62% from 60.4% in the prior year.
Expansion Plans: New Hospitals and More Beds
Tripling Bed Capacity by 2029
Currently, Artemis operates 700–800 beds. Through its ambitious expansion plan, the company targets 2,000–2,300 beds by 2029. This represents nearly a tripling of capacity within five years. To achieve this, Artemis is pursuing both greenfield and brownfield opportunities across key cities.
New Hospital Projects
Two major new hospitals are in the pipeline. First, a 300-bed super specialty hospital in Raipur, Chhattisgarh, is set to become operational by April–May 2026. The CapEx for this facility is INR 100 crore, funded through a mix of accruals and an ISC fund.
Second, a 650-bed super specialty hospital in South Delhi is planned. Construction is expected to begin by April–May 2026, with operations commencing in FY2029. The cost per bed is estimated at INR 75–80 lakh, which is competitive for the Delhi market.
Gurugram Flagship Expansion
In addition to new hospitals, Artemis plans to add over 100 beds at its Gurugram facility through a Platinum Green Building Certification. Furthermore, an additional purchase of Floor Area Ratio (FAR) will enable roughly 200 more beds — ultimately bringing total Gurugram capacity to 1,000 beds.
International Revenue Drives Growth
International patient revenue surged 34.9% year-on-year in Q3 FY26. Importantly, international patients now contribute 34% of total revenues, making them the single largest revenue segment. Key source regions include the UAE, Africa, CIS countries, and Scandinavia.
This strong performance reflects Artemis’s growing reputation in medical tourism and quaternary care. Additionally, its first overseas hospital — Artemis Curepipe Hospital in Mauritius — began operations in FY24. A second 110-bed international facility, Artemis Cascavelle Hospital in Mauritius, is announced for FY26.
Risks and Challenges Ahead
Despite the promising outlook, execution risks remain significant. Delays in construction, regulatory approvals, or cost overruns could impact both timelines and profitability. Moreover, the cardiac care and Daffodils segments have shown subdued performance, requiring efforts to improve patient mix and realization.
The QIP fundraise may also lead to equity dilution for existing shareholders. Therefore, investors should monitor the deployment efficiency of the raised capital alongside debt levels.
What Investors Should Watch
Key catalysts for Artemis Medicare include the operationalisation of the Raipur hospital, commencement of South Delhi construction, and continued traction in medical tourism. Analysts at Choice Institutional Equities forecast revenue, EBITDA, and PAT CAGRs of 26.1%, 28.9%, and 31.3% respectively through FY28.
However, the successful completion of the QIP and the improvement in quarterly EBITDA margins will be the most critical indicators of whether the company can execute its ambitious growth story.
